Waelbroeck Magali
Department of Biochemistry and Nutrition, School of Medicine, Université Libre de Bruxelles, Bât G/E, CP 611, 808 Route de Lennik, B-1070 Bruxelles, Belgium.
Neurochem Res. 2003 Apr;28(3-4):419-22. doi: 10.1023/a:1022888332221.
The binding properties of muscarinic acetylcholine receptors are affected by various drugs acting at a second (allosteric) binding site, usually (but not always) at supratherapeutic concentrations. Allosteric drugs acting at GABA receptors present advantages over competitive drugs; this explains the interest raised by allosteric effects on muscarinic receptors. A theoretical and practicable definition of allosteric drugs acting at muscarinic receptors will be given in this work, together with a summary of recent data concerning the number, position, and structural requirements of their binding sites.
毒蕈碱型乙酰胆碱受体的结合特性会受到作用于第二个(变构)结合位点的各种药物的影响,这些药物通常(但并非总是)处于超治疗浓度。作用于GABA受体的变构药物比竞争性药物具有优势;这解释了变构效应作用于毒蕈碱受体所引发的研究兴趣。本文将给出作用于毒蕈碱受体的变构药物的理论及实用定义,同时总结有关其结合位点的数量、位置和结构要求的最新数据。